Myeloma Investment Fund Invests in Envisagenics, A.I.-Driven Biotechnology Company

July 29, 2024

The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced an investment in Envisagenics, a biotechnology company at the forefront of RNA splicing technology.